Vanda Pharmaceuticals Announces Presentations at DDW 2022

Rhea-AI Summary

Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced its participation at Digestive Disease Week (DDW) 2022, taking place from May 21-24 in San Diego, CA. The company will present two significant studies by Dr. Sandra Paulina Smieszek, Head of Genetics. The first presentation on May 21 focuses on macrophage polarization in gastroparesis, while the second on May 23 discusses the gene set enrichment analysis in Ehlers Danlos syndrome patients with gastroparesis. For more details, visit DDW's website.

Positive

• Participation in a prestigious conference (DDW 2022) enhances visibility for Vanda.
• Presentation of two significant research studies could attract investor interest.

Negative

• None.

WASHINGTON, May 19, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at Digestive Disease Week (DDW) 2022, to be held in San Diego, CA and online from May 21-24, 2022.

The following will be presented:

May 21, 2022

Presentation Title: "THE ROLE OF M1 TO M2 MACROPHAGE POLARIZATION IN THE ETIOLOGY OF IDIOPATHIC GASTROPARESIS: GWAS PERSPECTIVE"
Abstract Number: 3752409
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics
Session Type: Plenary Session
Session Title: Late-Breaking Basic Science Abstract Plenary
Session Time: 2:00 PM to 3:30 PM PDT
Presentation Time: 2:15 PM to 2:30 PM PDT

May 23, 2022

Presentation Title: "ENRICHMENT OF PATIENTS WITH EHLERS DANLOS SYNDROME IN IDIOPATHIC GASTROPARESIS – A GENE SET ENRICHMENT ANALYSIS"
Abstract Number: 3696881
Presenter: Dr. Sandra Paulina Smieszek, Head of Genetics
Session Type: Poster Session
Session Title: Cell Biology, Biochemistry and Integrative Physiology
Session Time: 12:30 PM to 1:30 PM PDT

For more information on DDW 2022, please refer to https://ddw.org/.

About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com 

Elizabeth Van Every
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com 

View original content:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-presentations-at-ddw-2022-301551750.html

SOURCE Vanda Pharmaceuticals Inc.

FAQ

What will Vanda Pharmaceuticals present at DDW 2022?

Vanda Pharmaceuticals will present studies on macrophage polarization in gastroparesis and gene enrichment analysis in Ehlers Danlos syndrome.

When is Vanda Pharmaceuticals participating in Digestive Disease Week 2022?

Vanda Pharmaceuticals will participate from May 21-24, 2022.

Who is presenting for Vanda Pharmaceuticals at DDW 2022?

Dr. Sandra Paulina Smieszek, Head of Genetics, will present Vanda's research at DDW 2022.

What topics will Vanda Pharmaceuticals cover in their presentations at DDW 2022?

The topics include macrophage polarization in gastroparesis and patient enrichment in Ehlers Danlos syndrome.

Where can I find more information about DDW 2022?

More information about DDW 2022 can be found on the official website at https://ddw.org.